Retention of critical platelet hemostatic functions of amotosalen-UVA pathogen-reduced cryoprecipitated fibrinogen complex.

Date publication

janvier 2026

Journal

Transfusion

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MANGIN Pierre

Tous les auteurs :
Tupin F, Mouriaux C, Gatmaitan M, Kaastrup K, Yegneswaran S, Corash L, Mangin PH

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41542858

Résumé

Cryoprecipitate Anti-Haemophilic Factor (CRYO-AHF) is enriched for fibrinogen, VWF, FVIII, FXIII and fibronectin, but has short post-thaw expiration due to risk of transfusion-transmitted infection (TTI) limiting availability for rapid treatment. Amotosalen-UVA pathogen reduction treatment (A-PRT) to manufacture pathogen-reduced cryoprecipitated fibrinogen complex (PRCFC) allows 5-day post-thaw expiration, reduces TTI risk, and facilitates early treatment of hemorrhage.

Mots clés

VWF, cryoprecipitate, fibrinogen, microfluidic assays, pathogen inactivation, platelets

Référence

Transfusion. 2026 01 16;: